Cell Therapy Development
Brochure: Cell Therapy Development
The Opto™ Cell Therapy Development 1.0 Workflow accelerates the creation of better therapeutics by enabling multiple functional assays to be performed on 1000s of individual T cells in a matter of days. Deeply characterize, profile, and map your T cell populations at the single-cell level to directly link behavior to gene expression.
Application Note: Profile and Recover Polyfunctional T Cells Using Multiplexed Cytokine Secretion Assays
Learn how you can easily profile multiple secreted cytokines from live T cells and multiplex with other functional assays.
Datasheet: Cytotoxicity Assay
Learn how to track the kinetics of T cell-tumor cell killing behavior in real time.
Datasheet: Single Cell Cytokine Assays
Review assay overview and results for measuring the release of up to three cytokines from T cells.
Webinar: Maximize Functional Characterization of Your Precious T Cell Samples
In this webinar, we introduce you to new capabilities in the Cell Therapy Development Suite designed to empower you to get the most out of your T cell samples, from understanding cytokine secretions to gene expression.
Datasheet: TCRseq Well Plate Kit
Review assay overview and results for recovering and amplifying T cell receptor alpha and beta chains.
Application Note: Directly Link T Cell Phenotype and Function to Genotype with the Opto Cell Therapy Development 1.0 Workflow
Review use cases for CAR-T cell screening and TCR discovery.
Poster: T Cell Functional Analytics on the Lightning Platform
See how you can rapidly visualize and analyze thousands of cell-cell interactions in a single-day workflow with live cell recovery.
Brochure: Lightning System
Find out how the Lightning platform lets you visualize diverse cell interactions, measure individual cell cytotoxicity, and recover cells of interest alive.
Poster: T Cell Functional Analytics
This poster describes in detail how to sequence and clone IDH1 R132H targeted monoclonal T cell receptors from CD4+ T cells, using the Beacon platform.